Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Pfizer Looks to Fill Void for Chemo Drug After Teva Discontinues Generic Version

Doctors are warning of a potential shortage and rationing began for vincristine as Pfizer represents the only manufacturer for the chemotherapy drug.

Read More »

PhRMA Predicts Dire Consequences for Pharma Industry if Pelosi Plan Passes

PhRMA CEO Stephen Ubl said House Speaker Nancy Pelosi’s plan would be “devastating” to the industry.

Read More »

U.S. prices for multiple sclerosis drugs are on the rise

A U.S. study suggests that annual costs of disease modifying treatments for multiple sclerosis more than quadrupled from 2006 to 2016 as several new, costly medicines entered the market.

Read More »

Novo Nordisk and Mylan Battle Over Generic Versions of Victoza

Denmark’s Novo Nordisk filed a lawsuit in a Delaware district court against generic drugmaker Mylan.

Read More »

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Roche Holding AG priced the company’s personalized cancer treatment Rozlytrek at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co. that was approved during 2018.

Read More »

Report: Projected Sales of 10 Top-Selling Drugs Through 2024

A report by Evaluate Pharma estimates prescription drug sales will hit $1.18 trillion by 2024, driven by cell and gene therapies.

Read More »

Senators Urge FDA to Take Action Against AveXis

Days after the U.S. FDA revealed data manipulation was involved in the early studies of Novartis’ multi-million dollar gene therapy for SMA, U.S. Senate members demanded the regulatory agency take action against AveXis, the company that developed Zolgensma.

Read More »

Top 200 Medicines Annual Report 2019: The king of medicines

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

Read More »

Canada enacts drug price crackdown

The Canadian government announced final regulations to reduce patented drug prices expected to save Canadians C$13.2 billion over a decade, overriding heavy pharma company opposition.

Read More »

Medicare to cover expensive cancer cell therapies

The U.S. Centers for Medicare and Medicaid Services finalized a decision to cover expensive cancer cell therapies sold by Gilead Sciences Inc. and Novartis AG.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom